Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 12, 2025
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
GlobeNewswire
·
May 12, 2025
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In- …
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement
GlobeNewswire
·
May 12, 2025
Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today addresses frequently asked stockholder …
IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
GlobeNewswire
·
May 12, 2025
Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell …
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 12, 2025
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities …
ArriVent BioPharma Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 First IND for …
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
GlobeNewswire
·
May 12, 2025
WARRINGTON, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …
Longevity Health Holdings, Inc. Announces Reverse Stock Split
GlobeNewswire
·
May 12, 2025
PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (NASDAQ: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on longevity and healthy aging, today announced that it has resolved to effect a reverse stock …
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
GlobeNewswire
·
May 12, 2025
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden Patient and Healthcare Community …
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
GlobeNewswire
·
May 12, 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today …
Belite Bio to Participate in Four Upcoming Investor Conferences
GlobeNewswire
·
May 12, 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical …
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 12, 2025
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB …
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
GlobeNewswire
·
May 12, 2025
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
GlobeNewswire
·
May 12, 2025
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s …
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025
GlobeNewswire
·
May 12, 2025
Successful completion of €30 Million capital increase, with strong international demand and oversubscription Awarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector ( …
Herpesyl Under Review: Does This Herpes Supplement Really Work for Herpes Virus Symptoms?
GlobeNewswire
·
May 12, 2025
Aurora, Colorado, May 12, 2025 (GLOBE NEWSWIRE) -- Humans have long battled many serious diseases and conditions. Through the ages, humanity developed its knowledge of medicine and science. But even today, there are many diseases and sicknesses that are …
Best Weight Loss Supplements in USA 2025: Top Diet Pills That Actually Work Fast For Real Results - Wolfson Brands Ltd
GlobeNewswire
·
May 12, 2025
New York City, May 12, 2025 (GLOBE NEWSWIRE) -- Introduction: Best Weight Loss Supplements …
Alterity Therapeutics Prominently Featured at the International MSA Congress
GlobeNewswire
·
May 12, 2025
– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden …
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
GlobeNewswire
·
May 12, 2025
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain …
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire
·
May 12, 2025
TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central …
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire
·
May 12, 2025
Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company …